Oral contraceptives containing drospirenone for premenstrual syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Lopez, Laureen M ^a   Kaptein, A ^b   Helmerhorst, F M ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; ETHINYLESTRADIOL; LEVONORGESTREL; PLACEBO;

ABDOMINAL PAIN; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; FUNCTIONAL DISEASE; HEADACHE; HUMAN; MASTALGIA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOCIAL BEHAVIOR; SYMPTOM; SYSTEMATIC REVIEW;

EID: 44949159814     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006586.pub2     Document Type: Review

References (53)

1. Foidart 2000 {published data only} Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. European Journal of Contraception & Reproductive Health Care 2000;5:124-34.
2. Freeman 2001 {published data only} Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. European Journal of Contraception & Reproductive Health Care 2002;7 Suppl 3:27-34; discussion 42-3.
3. *Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al.Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women's Health & Gender-based Medicine 2001;10:561-9.
4. Pearlstein 2005 {published data only} Borenstein J, Wyrwich K, Niknian M, Marr J, Korner P, Yonkers K. Determining clinically meaningful benefit in the treatment of premenstrual dysphoric disorder (abstract). Obstetrics & Gynecology 2006;107:15S.
5. *Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21.
6. Sangthawan 2005 {published data only} Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3mg or levonorgestrel 150 μg on premenstrual symptoms. Contraception 2005;71:1-7.
7. Yonkers 2005 {published and unpublished data} Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics & Gynecology 2005;106:492-501.
8. Apter 2003 *Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, et al.Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception & Reproductive Health Care 2003;8:37-51.
9. Mansour D. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. European Journal of Contraception & Reproductive Health Care 2002;7 Suppl 3:35-41; discussion 42-3.
10. Borges 2006 Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle MEHD, Isaia CF, et al.Effect of a combination of ethinylestradiol 30 μg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 2006;74:446-50.
11. Coffee 2006 Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. American Journal of Obstetrics and Gynecology 2006;195:1311-9.
12. Joffe 2005 Joffe H, Hall JE, Soares CN, Gottschall H, Cohen LS. Oral contraceptive pills to treat premenstrual worsening of depression. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA 2005.
13. Parsey 2000 Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11.
14. ACOG 2000 American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin 2000; Vol. 15, issue 9 pp.
15. Als-Nielsen 2003 Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-8.
16. APA 2000 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IVTR). www.psychiatryonline.com/dsmLibrary.aspx (accessed 03 October 2006).
17. Blake 1998 Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. Journal of Psychosomatic Research 1998;45:307-18.
18. Connolly 2001 Connolly M. Premenstrual syndrome: an update on definitions, diagnosis and management. Advances in Psychiatric Treatment 2001;7:469-77.
19. Deeks 2001a Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM, SmithGD, AltmanDG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd Edition. London: BMJ Publishing Group, 2001:285-312.
20. Deeks 2001b Deeks JJ, Altman DG. Effect measures for meta-analysis of trials with binary outcomes. In: EggerM, SmithGD, AltmanDG editor (s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd Edition. London: BMJ Publishing Group, 2001:313-35.
21. Endicott 1993 Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 1993;29:321-6.
22. Endicott 2006 Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Archives of Women's Mental Health 2006;9:41-9.
23. FDA 2006 US Food, Drug Administration. Drug details. YAZ. Label and approval history. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails (accessed 22 June 2007).
24. Foidart 2005 Foidart JM. Added benefits of drospirenone for compliance. Climacteric 2005;8 Suppl 3:28-34.
25. Ford 2006 Ford O, Lethaby A, Mol B, Roberts H. Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD003415. DOI:10.1002/14651858.CD003415.pub2.
26. Gallo 2005 Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms versus >20 mcg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005;71:162-9.
27. Gallo 2006 Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2006, Issue 1.Art. No.: CD003987. DOI: 10.1002/14651858.CD003987.pub2.
28. Golding 2000 Golding JM, Taylor DL, Menard L, King MJ. Prevalence of sexual abuse history in a sample of women seeking treatment for premenstrual syndrome. Journal of Pyschosomatic Obstetrics and Gynecology 2000;21:69-80.
29. Haywood 2002 Haywood A, Slade P, King H. Assessing the assessment measures for menstrual cycle symptoms. A guide for researchers and clinicians. Journal of Pyschosomatic Obstetrics and Gynecology 2002;52:223-37.
30. Haywood 2007 Haywood A, Slade P, King H. Psychosocial associates of premenstrual symptoms and the moderating role of social support in a community sample. Journal of Pyschosomatic Obstetrics and Gynecology 2007;62:9-13.
31. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. www.cochrane.dk/cochrane/handbook/hbook.htm (accessed 1 June 2005).
32. Hunter 2002 Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of Pyschosomatic Obstetrics and Gynecology 2002;23:193-199.
33. Johnson 2004 Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: A clinical primer for practitioners. Obstetrics and Gynecology 2004;104:845-59.
34. Kroll 2006 Kroll R, Rapkin AJ. Treatment of premenstrual disorders. Journal of Reproductive Medicine 2006;51:359-70.
35. Kurshan 2006 Kurshan N, Epperson CN. Oral contraceptives andmood in women with and without premenstrual dysphoria: a theoretical model. Archives of Women's Mental Health 2006;9:1-14.
36. Lexchin 2003 Lexchin J, BeroL A, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
37. Moher 2001 Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001;357:1191-4.
38. Moos 1968 Moos RH. The Development of a Menstrual Distress Questionnaire. Psychosomatic Medicine 1968;30:853-67.
39. Mortola 1990 Mortola JF, Girton L, Beck L, Yen SSC. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: The Calendar of Premenstrual Experiences. Obstetrics & Gynecology 1990;76:302-7.
40. O'Brien 1979 O'Brien PMS, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. British Journal of Obstetrics and Gynaecology 1979;86:142-7.
41. Oelkers 2004 Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Molecular and Cellular Endocrinology 2004;217:255-61.
42. Paoletti 2004 Paoletti AM, Lello S, Fratta S, Orrù M, Ranuzzi F, Sogliano C, et al.Psychological effect of the oral contraceptive formulation containing 3mg of drospirenone plus 30 ?g of ethinyl estradiol. Fertility and Sterility 2004;81:645-51.
43. Phillips 2003 Phillips A, Haudiquet V. ICH E9 guideline 'Statistical principles for clinical trials': a case study. Statistics in Medicine 2003;22:1-11; discussion 13-7.
44. Rapkin 2003 Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28 Suppl 3:39-53.
45. Ross 2003 Ross C, Coleman G, Stojanovska C. Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology. Journal of Psychosomatic Obstetrics and Gynaecology 2003;24:163-74.
46. Sackett 2000 Sackett DL, Strauss SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. Second Edition. New York: Churchill Livingstone, 2000.
47. Schmidt 1998 Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine 1998;338:209-16.
48. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-12.
49. Schulz 2002a Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
50. Schulz 2002b Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-5.
51. Sitruk-Ware 2005 Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Update 2005;12:169-78.
52. Wang 1995 Wang M, Hammarbäck S, Lindhe B-Å, Bächström T. Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study. Acta Obstetricia et Gynecologica Scandinavica 1995;74:803-8.
53. Winer 2006 Winer SA, Rapkin AJ. Premenstrual disorders. Prevalence, etiology and impact. Journal of Reproductive Medicine 2006;51:339-47.